Key statistics
On Thursday, Inhibikase Therapeutics Inc (IQT0:MUN) closed at 2.50, -25.01% below its 52-week high of 3.33, set on Jan 25, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.00 |
---|---|
High | 2.50 |
Low | 2.50 |
Bid | -- |
Offer | -- |
Previous close | 2.50 |
Average volume | 0.00 |
---|---|
Shares outstanding | 65.77m |
Free float | 58.89m |
P/E (TTM) | -- |
Market cap | 189.43m USD |
EPS (TTM) | -2.93 USD |
Data delayed at least 15 minutes, as of Oct 31 2024 07:07 BST.
More ▼
Announcements
- Inhibikase Therapeutics Announces Closing of up to $275 Million Financing and Advancement of IkT-001Pro into a Late Stage Clinical Trial in Pulmonary Arterial Hypertension
- Inhibikase Therapeutics Announces Pricing of $110 Million Private Placement to Advance IkT-001Pro, an Optimized Prodrug of Imatinib, into a Late-Stage Trial in Pulmonary Arterial Hypertension
- Inhibikase Therapeutics Reports Second Quarter Financial Results and Highlights Recent Period Activity
- Inhibikase Therapeutics to Report Second Quarter 2024 Financial Results on August 14, 2024
- Inhibikase Therapeutics Completes Enrollment of the Phase 2 ‘201’ Trial Evaluating Risvodetinib in Untreated Parkinson’s Disease
- Inhibikase Therapeutics Announces Expansion to its Therapeutic Pipeline and Updates its Research and Development Programs
- Inhibikase Therapeutics Announces Pricing of Registered Direct Offering and Warrant Inducement, Priced At-The-Market for Aggregate Gross Proceeds of $4.0 Million
- Inhibikase Therapeutics Reports First Quarter Financial Results and Highlights Recent Period Activity
- Inhibikase Therapeutics Announces Request for Withdrawal of S-1 Registration Statement
- Inhibikase Therapeutics Announces Final Pre-IND Meeting Outcomes for IkT-001Pro as a Treatment for Pulmonary Arterial Hypertension
More ▼